A polypill for preventing cardiovascular disease has the potential to address health inequities and expand health care access for low-income populations.
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).
Patients with diabetes and chronic kidney disease receiving physiologic insulin resensitization had much lower annual costs of care than similar patients not receiving it.